Portola Pharmaceuticals Inc (NASDAQ:PTLA) Move as Institutional Investors’ Sentiment Increased

January 21, 2018 - By Migdalia James

 Portola Pharmaceuticals Inc (NASDAQ:PTLA) Move  as Institutional Investors' Sentiment  Increased

Sentiment for Portola Pharmaceuticals Inc (NASDAQ:PTLA)

Portola Pharmaceuticals Inc (NASDAQ:PTLA) institutional sentiment increased to 2.16 in Q3 2017. Its up 0.85, from 1.31 in 2017Q2. The ratio is positive, as 123 active investment managers increased and started new equity positions, while 57 decreased and sold stock positions in Portola Pharmaceuticals Inc. The active investment managers in our partner’s database reported: 56.33 million shares, up from 48.64 million shares in 2017Q2. Also, the number of active investment managers holding Portola Pharmaceuticals Inc in their top 10 equity positions decreased from 7 to 5 for a decrease of 2. Sold All: 20 Reduced: 37 Increased: 85 New Position: 38.

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company has market cap of $3.24 billion. The firm is developing Betrixaban, an oral once-daily inhibitor of Factor Xa that is in Phase III clinical stage for extended duration VTE prophylaxis in acute medically ill patients for 35 days of in-hospital and post-discharge use; Andexanet alfa, a recombinant protein, which is in Phase III and IV stages for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, an orally available dual kinase inhibitor, which is in Phase IIa clinical stage for hematologic, blood, cancers, and inflammatory disorders. It currently has negative earnings. It also develops Syk-selective inhibitors in pre-clinical stage for allergic conjunctivitis.

The stock decreased 0.12% or $0.06 during the last trading session, reaching $49.63. About 648,219 shares traded. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has risen 51.17% since January 21, 2017 and is uptrending. It has outperformed by 34.47% the S&P500.

Analysts await Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) to report earnings on February, 27. They expect $-1.52 EPS, down 60.00 % or $0.57 from last year’s $-0.95 per share. After $-1.41 actual EPS reported by Portola Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 7.80 % negative EPS growth.

Fernwood Investment Management Llc holds 7.77% of its portfolio in Portola Pharmaceuticals, Inc. for 229,577 shares. Partner Fund Management L.P. owns 5.08 million shares or 5.39% of their US portfolio. Moreover, Cormorant Asset Management Llc has 4.77% invested in the company for 500,000 shares. The California-based Partner Investment Management L.P. has invested 4.18% in the stock. Sectoral Asset Management Inc, a Quebec – Canada-based fund reported 506,414 shares.#img1#

Since January 1, 0001, it had 0 insider buys, and 1 insider sale for $563,950 activity.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Ratings Coverage

Ratings analysis reveals 100% of Portola Pharmaceuticals’s analysts are positive. Out of 6 Wall Street analysts rating Portola Pharmaceuticals, 6 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $24 while the high is $81. The stock’s average target of $75.67 is 52.47% above today’s ($49.63) share price. PTLA was included in 33 notes of analysts from August 5, 2015. The rating was maintained by Cowen & Co with “Buy” on Monday, June 26. The rating was upgraded by Oppenheimer to “Outperform” on Friday, February 24. Oppenheimer maintained the stock with “Buy” rating in Thursday, December 28 report. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has “Buy” rating given on Monday, June 26 by Morgan Stanley. The company was maintained on Tuesday, December 19 by Oppenheimer. The company was maintained on Wednesday, September 20 by Credit Suisse. As per Monday, August 28, the company rating was maintained by Oppenheimer. The company was upgraded on Tuesday, January 3 by Citigroup. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has “Outperform” rating given on Monday, March 28 by Credit Suisse. Credit Suisse maintained Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) on Tuesday, December 27 with “Outperform” rating.

More recent Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) news were published by: Fool.com which released: “Here’s Why Portola Pharmaceuticals Inc. Tanked as Much as 10%” on December 26, 2017. Also Streetinsider.com published the news titled: “Portola Pharma (PTLA) Reports Update on Biologics License Application (BLA …” on December 22, 2017. Seekingalpha.com‘s news article titled: “Portola Pharmaceuticals: What The AndexXa Approval Delay Means?” with publication date: December 24, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: